Novavax Submits Vaccine for Approval as Ottawa Seeks EU Reassurances on Export Rules

A dose of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London on October 7, 2020. Alastair Grant/AP/The Canadian Press

OTTAWA—The federal government is reviewing a new COVID-19 vaccine that has been submitted for regulatory approval.

Maryland-based Novavax quietly applied on Friday for Health Canada to approve its vaccine, which studies have suggested is effective against the British and South African variants of the virus.